Get it on Google Play

Altimmune receives FDA fast track designation for pemvidutide in AUD

August 19, 2025 7:30 AM EDT Send to a Friend
Altimmune Inc. (NASDAQ: ALT) announced that the U.S. Food and Drug Administration has granted fast track designation to pemvidutide for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login